This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23; On-demand experience Delivered September 28-30Boston Convention and Exhibition Center

Sarah Blackmore
Viral Vector and Gene Therapy Technology Manager at Pall Biotech

Profile

Sarah Blackmore currently has the role of Viral Vector and Gene Therapy Technology Manager at Pall Biotech. She previously worked on the Pall Bioprocess Specialist team supporting process development projects with Pall technologies in the Northeast region from 2016-2021, with a focus on antibody, protein, vaccine, gene therapy and oligonucleotide processes. Before joining Pall, Sarah held roles in purification manufacturing and downstream process development at Amgen. She graduated from Cornell University with a bachelor’s degree in Biological Sciences and from Brown University with a master’s degree in Biotechnology.

Agenda Sessions

  • ROOM 208: Use of Mustang® E Membrane Chromatography as Risk Mitigation for Endotoxin and Viral Clearance Contamination During UF/DF Processing

    12:05pm
  • Use of Mustang® E Membrane Chromatography as Risk Mitigation for Endotoxin and Viral Clearance Contamination During UF/DF Processing

    2:15pm